Active Vascular Endothelial Growth Factor C (VEGFC) Homo sapiens (Human) Active protein

VEGF-C; Flt4-L; VRPL; Vascular Endothelial Growth Factor-Related Protein

Add to Cart Distributors
Overview
Properties
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
  • Traits Freeze-dried powder, Purity > 90%
  • Isoelectric Point8.2
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active Vascular Endothelial Growth Factor C (VEGFC) Packages (Simulation)
  • Active Vascular Endothelial Growth Factor C (VEGFC) Packages (Simulation)
  • Active Vascular Endothelial Growth Factor C (VEGFC) Figure . Gene Sequencing (extract)
  • APA145Hu01.jpg Figure. SDS-PAGE
  • Active Vascular Endothelial Growth Factor C (VEGFC) Figure. Western Blot; Sample: Recombinant VEGFC, Human.
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

Vascular endothelial growth factor C (VEGFC) is a protein that is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family. It plays key roles in the physiology and pathology of many aspects of the cardiovascular system, including vasculogenesis, hematopoiesis, angiogenesis and vascular permeability. To test the effect of VEGFC on cell proliferation of ECV304 endothelium cell line, cells were seeded into triplicate wells of 96-well plates at a density of 2,000cells/well and allowed to attach overnight, then the medium was replaced with serum-free standard DMEM prior to the addition of various concentrations of VEGFC. After incubated for 72h, cells were observed by inverted microscope and cell proliferation was measured by Cell Counting Kit-8 (CCK-8). Briefly, 10µL of CCK-8 solution was added to each well of the plate, then measure the absorbance at 450nm using a microplate reader after incubating the plate for 1-4 hours at 37°C. The dose-effect curve of VEGFC was shown in Figure 1. It was obvious that VEGFC significantly promoted cell proliferation of ECV304 cells. The ED50 for this effect is typically 0.304 to 1.339µg/mL.

Usage

Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Alternatively activated RAW264. 7 macrophages enhance tumor lymphangiogenesis in mouse lung adenocarcinomaPubMed: 19241443
  • Expression of COX-2 and VEGF-C in cholangiocarcinomas at different clinical and pathological stagesPubMed: 26125824
  • Fenofibrate inhibits the expression of VEGFC and VEGFR-3 in retinal pigmental epithelial cells exposed to hypoxiaPubMed: 26622498
  • IL-10 Indirectly Regulates Corneal Lymphangiogenesis and Resolution of Inflammation via MacrophagesPubMed: 26608451
  • Interleukin-6 Induces Vascular Endothelial Growth Factor-C Expression via Src-FAK-STAT3 Signaling in Lymphatic Endothelial Cells.pubmed:27383632
  • RNAi-mediated gene silencing of vascular endothelial growth factor C suppresses growth andinduces apoptosis in mouse breast cancer in vitro and in vivo.pubmed:27895746
  • Characterization of isolated liver sinusoidal endothelial cells for liver bioengineeringPubmed:29582235
  • Effects of diphyllin as a novel V-ATPase inhibitor on TE-1 and ECA-109 cellsPubmed:29328465
  • Dynamic signature of lymphangiogenesis during acute kidney injury and chronic kidney diseasePubmed: 31019289
  • Isotretinoin does not alter VEGF-A and VEGF-C levels: Do retinoids behave differently in dose-dependent and/or in vivo/in vitro conditions?Pubmed: 32722957

Recommend products